<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609671</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00013603</org_study_id>
    <nct_id>NCT03609671</nct_id>
  </id_info>
  <brief_title>Emotions Immunology and Breast Cancer</brief_title>
  <official_title>A Pilot Study: Emotions Immunology and Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luz A. Venta, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Methodist Hospital System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study representing a proof of concept regarding the potential for immune system
      enhancement with psychotherapy, resulting in improved immunological response at lumpectomy or
      mastectomy in patients undergoing neoadjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will receive be randomized to the experimental group (receive
      individualized psychotherapy + standard of care) or the control group (standard of care) and
      both groups will complete psychological questionnaires. Both groups will have blood sampling
      and have their biopsied tissue read for immunological factors.

      Patients with triple negative breast cancer or with breast cancers presenting at a large size
      (greater than one centimeter) have a worst prognosis than other types of breast cancer or
      cancers that are diagnosed when smaller than one centimeter. For these patients, neoadjuvant
      chemotherapy, that is chemotherapy given before surgical removal of the cancer, is often
      used. Common indications for using neoadjuvant therapy include: available clinical trial,
      learning about the tumor response in vivo to a particular chemotherapy and shrinking the
      tumor so as to convert a mastectomy to a lumpectomy at the time of resection. In patients
      receiving neoadjuvant treatment, there is usually 6-months between the diagnosis and the
      surgical breast tumor resection during which the chemotherapy is administered, and during
      that time patients are offered support group therapy. Although the prognosis for breast
      cancer patients has improved, this subset of patients still poses a clinical challenge.

      Growing evidence in the psychological field has documented a link between the immune system
      and psychological factors, emphasizing that stress and trauma are detrimental to the ability
      and effectiveness of the immune system and emphasizing that mental health has an importance
      not only in and of itself on how the person feels, but also translates into physical health
      at least in part through the immune system. Personality traits and other emotional factors
      remain as viable candidates contributing to the development of malignancies, but the research
      in this area is confusing. For example, many authors report that depressed women are more
      prone to develop breast cancer than others, while other research has failed to find such a
      connection.

      Nevertheless, many clinicians notice that cancer tends to present after a major loss or
      emotional trauma. Some research suggests that the suppression of negative emotions or
      difficulty expressing emotions such as anger and hostility are characteristic of the
      cancer-prone personality, so that in a typical study, clinicians who interviewed patients
      prior to breast biopsy were able to predict the presence of a malignancy in 94% of cases
      based on psychological factors alone. Similarly, a study has been able to predict with 75%
      accuracy those patients who had early cancer with no knowledge of their Pap smear results,
      based on the presence of extreme hopelessness. However, although there are many similar
      studies, other researchers have not been able to confirm the importance of emotional factors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 23, 2015</start_date>
  <completion_date type="Actual">March 18, 2019</completion_date>
  <primary_completion_date type="Actual">March 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to two groups.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Questionnaire#1, Adverse Childhood Experience (ACE).</measure>
    <time_frame>Baseline pre-chemotherapy and post-chemotherapy (about 4-6 months later).</time_frame>
    <description>The self-reported Adverse Childhood Experience Questionnaire measures different types of abuse, neglect, and other hallmarks of a challenging childhood. Scores range from 0-10, with 10 indicating highest childhood abuse &amp;/or neglect exposure with greater risk for negative consequences later in life, and 0 is lowest exposure and lower risk for negative consequences.questionnaires with immune responses. Pathologic tumor response is our measurable endpoint, focusing on immune cells in the tumor bed at lumpectomy or mastectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire#2, Depression, Anxiety, and Stress Scale (DASS).</measure>
    <time_frame>Baseline pre-chemotherapy and post-chemotherapy (about 4-6 months later).</time_frame>
    <description>The self-reported Depression, Anxiety, and Stress Scale Questionnaire is 3-part tool that measures motional states of depression, anxiety, and stress. Scores range from 0-42 for depression, 0-42 for anxiety and 0-42 for stress. A score closer to 42 for each state is indicative of extremely severe symptoms while a score closer to 0 indicates normal to mild symptom scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire#3, Experiences in Close Relationships-Revised (ECR-R).</measure>
    <time_frame>Baseline pre-chemotherapy and post-chemotherapy (about 4-6 months later).</time_frame>
    <description>The self-reported Experiences in Close Relationships-Revised Adult Attachment Questionnaire is a tool that measures how an individual behaves in relationships with others. Scores range from 0-5. A score closer to 0 is indicative of attachment while a score closer to 5 indicates signs of attachment-avoidance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire#4, Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B, version 4).</measure>
    <time_frame>Baseline pre-chemotherapy and post-chemotherapy (about 4-6 months later).</time_frame>
    <description>The self-reported Functional Assessment of Cancer Therapy Questionnaire is a tool that measures how an individual behaves in relationships with others. Scored in a 5 point scale with a total score ranging from 0 to 164, with a higher score indicative of better health related quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire#5, Benefit Finding Scale (BFS).</measure>
    <time_frame>Baseline pre-chemotherapy and post-chemotherapy (about 4-6 months later).</time_frame>
    <description>The self-reported Benefit Finding Questionnaire is a tool that measures how an individual might feel their cancer diagnosis contributes to their outlook on life. Scored in a 5 point scale with total scores ranging from 17-85. Higher scores indicate more benefit derived from breast cancer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Questionnaire#6, Acceptance and Action Questionnaire - II (AAQ-II)</measure>
    <time_frame>Baseline pre-chemotherapy and post-chemotherapy (about 4-6 months later).</time_frame>
    <description>The self-reported Acceptance and Action Questionnaire - II is a tool that measures psychological inflexibility and experiential avoidance. Score in a 7 point scale, range 7 to 49. A higher score indicates greater levels of psychological inflexibility .</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Emotions</condition>
  <condition>Immunology</condition>
  <arm_group>
    <arm_group_label>Standard of Care + Intervention (Individualized Therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention (individualized therapy) plus Standard of Care, and the completion of a psychological questionnaire at chemotherapy start and at the end, approximately four to six months later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group: Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care plus the completion of a psychological questionnaire at the beginning of the chemotherapy and at the end, approximately four to six months later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard of Care + Experimental Individualized Therapy</intervention_name>
    <description>Participants will receive standard of care plus supportive psychotherapy for a one hour, weekly, during the time they are undergoing neoadjuvant treatments.</description>
    <arm_group_label>Standard of Care + Intervention (Individualized Therapy)</arm_group_label>
    <other_name>Individualized Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control: Standard of Care</intervention_name>
    <description>Participants will undergo standard of care only (no Intervention/no individualized therapy) .</description>
    <arm_group_label>Control Group: Standard of Care</arm_group_label>
    <other_name>No intervention</other_name>
    <other_name>No Individualized Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-pregnant adult (eighteen years old or older) women with a diagnosis of breast
             cancer

          -  Planned to receive neoadjuvant chemotherapy for about six month duration

          -  Must be fluent in speaking, reading and writing English

          -  Not planning on undergoing individual psychotherapy during the study time outside the
             study.

          -  Biopsy procedure to be performed with surgical treatment planned at Houston Methodist
             System

        Exclusion Criteria:

          -  Pregnant or planned to become pregnant

          -  Patient not fluent in English

          -  Patients undergoing individual psychotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luz A. Venta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Hospital Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>[1.] Baumeister, D., et al. Childhood trauma and adult inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumor necrosis factor-Î±. Molecular Psychiatry: 2015: 1-8. [2.] Bleiker, E.M. et al. Personality factors and breast cancer development: a prospective longitudinal study. Journal of the National Cancer Institute; 1996: 1478-1482. [3.] Brod, S., et al. 'As above, so below.&quot; Examining the interplay between emotion and the immune system. Immunology, 2014: 143, 311-318. [4.] Buchheim A, Viviani R, Taubner S, et al. EPA-0142 - Neural changes in depressed patients during psychodynamic psychotherapy: An fMRI Study. European Psychiatry [serial online]. January 1, 2014;29(1, Number 1 Supplement 1):1. [5.] Carrig M, Kolden G, Strauman T. Using functional magnetic resonance imaging in psychotherapy research: A brief introduction to concepts, methods and task selection. Quantitative and qualitative methods in psychotherapy research [e-book]. New York, NY, US: Routledge/Taylor &amp; Francis Group; 2014:72-84. [6.] Dumas J, Makarewicz J, Newhouse P, et al. Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study. Brain Imaging And Behavior [serial online]. December 1, 2013;7(4):524-532. [7.] Spiegel, D. Minding the body: Psychotherapy and cancer survival. British Journal of Health Psychology, 2014, 19: 465-485. [8.] Temoshok L. Personality, coping style, emotion and cancer: towards an integrative model. Cancer Surv 1987:6:545-67. [9.] Wirsching, M., et al., Psychological identification of breast cancer patients before biopsy. Journal of Psychosomatic Research, 1982: 26(1): 1-10. [10.] Zonderman AB, et al. Depression as a risk for cancer morbidity and mortality in a nationally representative sample. JAMA 1989;262:1191-5. [11.] Persky VW, et al. Personality and risk of cancer: 20-year follow-up of the Western Electric Study. Psychosom Med 1987;49:435-49. [12.] Chida, Y., Hamer, M., Wardle, J., &amp; Steptoe, A. (2008). Do stress-related psychosocial factors contribute to cancer incidence and survival?. Nature Clinical Practice. Oncology, 5(8), 466-475. doi:10.1038/ncponc1134 [13.] Fagundes, C. P., Lindgren, M. E., &amp; Kiecolt-Glaser, J. K. (2013). Psychoneuroimmunology and Cancer: Incidence, Progression, and Quality of Life. In Psychological Aspects of Cancer (pp. 1-11). Springer US. [14.] Lillberg, K., Verkasalo, P. K., Kaprio, J., Teppo, L., Helenius, H., &amp; Koskenvuo, M. (2003). Stressful life events and risk of breast cancer in 10,808 women: a cohort study. American Journal Of Epidemiology, 157(5), 415-423. [15.] Lutgendorf, S. K., Johnsen, E. L., Cooper, B., Anderson, B., Sorosky, J. I., Buller, R.E., &amp; Sood, A. K. (2002). Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer, 95(4), 808-815. [16.] Lutgendorf, S. K., Lamkin, D. M., Jennings, N. B., Arevalo, J. G., Penedo, F., DeGeest, K., &amp; ... Sood, A. K. (2008). Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research, 14(21), 6839 6846. doi:10.1158/1078-0432.CCR-08-0230 [17.] Pocock, S.J., &amp; Simon, R. (1975). Sequential Treatment Assigment with Balancing for Prognostic Factors in the Controlled Clinical Trial, Biometrics, 31(1), 103-115. doi.org/10.2307%2F2529712 [18.] Han, B., Enas, N. H. and McEntegart D. (2009). Randomization by minimization for unbalanced treatment allocation. Statistics in Medicine, 28(27), 3329-3346.</citation>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital System</investigator_affiliation>
    <investigator_full_name>Luz A. Venta, MD</investigator_full_name>
    <investigator_title>Principal Investigator, Houston Methodist Hospital Physician</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Emotions Immunology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>to be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

